Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 14/20 | 0.39 |
| ▸ | DLK1 | P80370 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774189 | 0.83 | NTRK1 (0.38) | PRMT5WDR77NTRK1GSK3BKIT | |
| SCHEMBL15185725 | 0.79 | CYP3A4 (0.44) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL15882593 | 0.79 | PLK4 (0.50) | PRMT5WDR77MAP3K12DLK1CDK2 | |
| SCHEMBL19754801 | 0.77 | PRMT5 (0.41) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL24565956 | 0.76 | PRMT5 (0.43) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL13523638 | 0.76 | MAP3K12 (0.47) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL22264317 | 0.75 | RPS6KA5 (0.42) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL21053645 | 0.73 | PRMT5 (0.41) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL31311028 | 0.73 | PRMT5 (0.41) | PRMT5WDR77MAP3K12DLK1 | |
| SCHEMBL1772696 | 0.73 | ALDH1A1 (0.50) | PRMT5WDR77MAP3K12DLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PRMT5 2445/4885WDR77 2667/4885ULK1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.